Viromed Medical AG seeks special approval for cold plasma device for the
prevention of ventilator-associated pneumonia (VAP)

EQS-News: Viromed Medical AG / Key word(s): Miscellaneous/Study
Viromed Medical AG seeks special approval for cold plasma device for the
prevention of ventilator-associated pneumonia (VAP)

10.07.2024 / 07:30 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Viromed Medical AG seeks special approval for cold plasma device for the
prevention of ventilator-associated pneumonia (VAP)

  * Targeted use of the antimicrobial effect of cold plasma beyond wound
    treatment

  * Use of cold plasma could revolutionize the treatment of VAP and
    significantly reduce mortality

  * Aiming for rapid special approval for own device in Germany and USA by
    2025

Pinneberg, 10 July 2024 - Viromed Medical AG (ISIN: DE000A3MQR65; "Viromed")
is launching a second pioneering study on the use of cold plasma for the
prevention of ventilator-associated pneumonia (VAP). The study, under the
scientific direction of Prof. Dr. Hortense Slevogt from the Hannover Medical
School (MHH) and two other world-renowned institutes, aims to obtain rapid
special approval for the PulmoPlas device developed by Viromed for this
innovative preventive measure in Germany and the USA.

The further development and standardization of cold plasma technology for
use in study-relevant cell cultures and later also in the human lung comes
from relyon plasma GmbH, a wholly owned subsidiary of TDK Electronics AG. As
a partner of Viromed, relyon plasma will establish the prototypes for the
application and ensure the standardized generation of cold plasma as well as
its characterization and consistency in the trial.

The exploitation rights are held by Viromed Medical AG.

VAP is a frequent and serious complication in mechanically ventilated
patients. It occurs in patients who are invasively mechanically ventilated
for at least 48 hours. Studies show that VAP occurs in 23 to 36 percent of
mechanically ventilated patients and is associated with prolonged
ventilation time and longer stays in the intensive care unit and hospital.
The estimated mortality rate is 10 to 13 percent. In Germany alone, there
were around 486,000 mechanically ventilated intensive care patients in 2023
and many thousands of deaths, with a strong upward trend. Many millions of
patients worldwide are mechanically ventilated every year. The use of cold
plasma against VAP would therefore have the potential to save hundreds of
thousands of lives every year.

Uwe Perbandt, CEO of Viromed Medical AG: "The use of cold plasma has already
proven very successful in the treatment of difficult-to-heal wounds. Our
vision is to use the antimicrobial effect in other areas of application
where treatment with conventional methods leads to unsatisfactory results.
If several hundred thousand patients die from VAP every year, this is
unacceptable. As a first mover, we are therefore systematically driving
forward the relevant research and striving to obtain special approval for
our PulmoPlas device as quickly as possible, as we see an urgent medical
need for a better solution to the VAP problem. At the same time, we are
tapping into an attractive market segment, as the global market for
mechanical ventilation is predicted to see solid growth averaging 8.2% per
year until 2032 due to the increase in chronic respiratory diseases."

Since October 2023, the MHH, in cooperation with Viromed Medical AG, has
been investigating the safety profile of the use of cold plasma in bacterial
infections of the respiratory tract using models of the respiratory mucosa.
In particular, the focus is on the potential of cold plasma to kill bacteria
that have infected the epithelium. In parallel, possibly associated
inflammatory reactions, possible changes in cell differentiation, cell
death, DNA damage as well as the therapeutic dose and the time window of
application are being investigated. In order to optimize the effectiveness
of different plasma compositions, their effectiveness in connection with
cell damage will be investigated differentially. Due to promising
preliminary results that have shown no damaging effect on the airway
epithelium, a second study is now starting in parallel, which was originally
planned for mid-2025. This will expand the investigation of the safety
profile of cold plasma on alveolar epithelium, taking into account
mechanical shear forces that act on the alveolar mucosa during breathing. In
addition, the potential and safety of cold plasma to kill bacteria applied
to precision-cut lung slices (PCLS) will be tested.

Prof. Dr. Hortense Slevogt, Clinic for Pneumology and Infectiology, MHH:
"Ventilator-associated pneumonia not only has a high mortality rate, it is
also a general burden on the healthcare system due to increased antibiotic
consumption, longer patient stays and higher treatment costs. The increasing
antibiotic resistance of pathogens also makes new, non-antibiotic approaches
urgently necessary. If the positive preliminary results of our study
continue to be confirmed and the safety of cold physical plasma in the human
lung is established, cold plasma has the potential to revolutionize the
treatment of ventilated patients."

About Viromed Medical AG:

Viromed Medical AG has a broad customer base in the DACH region, including
various DAX companies, e.g. Volkswagen and Lufthansa, as well as federal
states and various federal ministries, 1,100 hospitals, 7,000 pharmacies,
and 17,000 medical practices.

Contact Viromed Medical AG

Uwe Perbandt
CEO
Flensburger Straße 18
25421 Pinneberg
Germany
Email: kontakt@viromed-medical.de
www.viromed-medical-ag.de


---------------------------------------------------------------------------

10.07.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        Viromed Medical AG
                   Flensburger Straße 18
                   25421 Pinneberg
                   Germany
   Phone:          +49 4101 809960
   E-mail:         kontakt@viromed-medical.de
   Internet:       https://www.viromed-medical-ag.de/
   ISIN:           DE000A3MQR65
   WKN:            A3MQR6
   Listed:         Regulated Unofficial Market in Berlin, Dusseldorf,
                   Hamburg
   EQS News ID:    1942511

End of News EQS News Service
---------------------------------------------------------------------------

1942511 10.07.2024 CET/CEST